Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Viking Therapeutics (VKTX – Research Report). The ...
Viking Therapeutics has announced positive results from its Phase Ib clinical trial of VK0214, a thyroid hormone receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback